Table 3.
SADRs in primary and non-primary medical institutions.
| Primary health institutions | Yes OR (95% CI) |
No OR (95% CI) |
|---|---|---|
| Gender (refer to male) | ||
| Female | 0.956 (0.91–1.003) | 1.034* (1.004–1.064) |
| Age (refer to 18–35) | ||
| 0–6 | 0.848* (0.742–0.969) | 0.950 (0.884–1.022) |
| 6–18 | 0.912 (0.805–1.034) | 1.208** (1.109–1.317) |
| 35–60 | 1.082* (1.005–1.166) | 1.324** (1.262–1.389) |
| 60–80 | 1.145** (1.062–1.234) | 1.496** (1.427–1.570) |
| > 80 | 1.225** (1.078–1.392) | 1.341** (1.253–1.435) |
| Number of diseases (refer to 1) | ||
| ≥ 2 | 1.394** (1.274–1.525) | 1.207** (1.166–1.250) |
| Polypharmacy (refer to no) | ||
| yes | 2.708** (1.613–4.548) | 3.332** (2.963–3.747) |
| Type of drug (refer to chemical compound) | ||
| Chinese patent medicine | 1.079** (1.022–1.139) | 0.936** (0.899–0.975) |
| Imported and biological product | 1.173 (0.990–1.390) | 1.392** (1.311–1.478) |
| Past history (refer to no) | ||
| Yes | 1.625** (1.222–2.161) | 1.884** (1.754–2.025) |
| Unknown | 0.789** (0.753–0.827) | 1.043** (1.011–1.075) |
| Past behavior (refer to no) | ||
| Smoking and drinking | 1.333** (1.242–1.430) | 1.198** (1.136–1.263) |
| Allergy | 0.875 (0.643–1.190) | 1.080 (0.982–1.189) |
| History of illness and surgery | 0.964 (0.752–1.234) | 1.304** (1.197–1.420) |
| Medication (refer to oral) | ||
| Injection | 7.353** (6.947–7.783) | 3.335** (3.205–3.469) |
| Others | 1.016 (0.742–1.392) | 1.054 (0.936–1.188) |
| Time from medication to ADR (refer to < 3) | ||
| ≥ 3 | 1.368** (1.221–1.533) | 2.312** (2.241–2.385) |
| Season (refer to spring) | ||
| Summer | 1.185** (1.109–1.265) | 1.033 (0.993–1.074) |
| Autumn | 1.387** (1.304–1.476) | 1.193** (1.150–1.238) |
| Winter | 1.560** (1.439–1.691) | 1.135** (1.085–1.186) |
| ADRs occurrence (refer to first) | ||
| Again | 0.768 (0.569–1.037) | 0.870** (0.792–0.956) |
| New adverse reactions (refer to no) | ||
| Yes | 1.597** (1.524–1.673) | 1.385** (1.342–1.429) |